+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
P

Actively Recruiting

This trial studies adults with advanced or recurrent non-small cell lung cancer NSCLC that has a specific EGFR exon 20 insertion mutation. It aims to evaluate how well the drug osimertinib works for this condition, focusing on tumor response rates, safety, and survival outcomes. The study also explores molecular markers related to treatment response and resistance. Participants receive oral osimertinib once daily in repeating 21-day cycles, continuing until their disease progresses or side effects become unacceptable. Throughout the trial, participants undergo heart function tests echocardiography or MUGA, imaging scans MRI or CT with contrast, and blood sample collections. After treatment, follow-up visits occur at 30 days and then every three months for up to five years. During the study, researchers monitor tumor response, progression-free survival, overall survival, and any adverse events. Molecular analyses are performed on tumor tissue and circulating tumor DNA to understand treatment effects and resistance. The total participation duration can last up to five years, including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
347 locations